Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone

Executive Summary

Teva has been able to hold onto a roughly 85% share of the Copaxone 40 mg market, but expects pressure from generics will intensify in the second half of the year.

Advertisement

Related Content

Enthusiasm For US Biosimilars Wanes For Some, But Not Others
Generic Drug Sector Struggles Even As The Need For Cheaper Drugs Grows
Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?
Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Teva Pushes CGRP Timeline Back To End Of 2018
Sandoz's Less Frequently Dosed Copaxone Generic Glatopa Hits Teva Two Months Early
Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce
Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle
Generic Manufacturers Try To Up Their Game As US Pressure Persists

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123530

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel